BR112013014387B1 - complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição - Google Patents

complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição Download PDF

Info

Publication number
BR112013014387B1
BR112013014387B1 BR112013014387A BR112013014387A BR112013014387B1 BR 112013014387 B1 BR112013014387 B1 BR 112013014387B1 BR 112013014387 A BR112013014387 A BR 112013014387A BR 112013014387 A BR112013014387 A BR 112013014387A BR 112013014387 B1 BR112013014387 B1 BR 112013014387B1
Authority
BR
Brazil
Prior art keywords
garcinol
extract
composition
cyclodextrin complex
preparation process
Prior art date
Application number
BR112013014387A
Other languages
English (en)
Other versions
BR112013014387A2 (pt
Inventor
Vishwaraman Mohan
Bhaskaran Sunil
Original Assignee
Indus Biotech Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indus Biotech Private Ltd filed Critical Indus Biotech Private Ltd
Publication of BR112013014387A2 publication Critical patent/BR112013014387A2/pt
Publication of BR112013014387B1 publication Critical patent/BR112013014387B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/01—Charge-transfer complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms

Abstract

complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição a presente invenção se refere a uma molécula farmacêutica de garcinol quimicamente complexado com ciclodextrinas e o uso da molécula complexada na prevenção e no tratamento da disfunção cardíaca induzida por quimioterapia, fármacos e/ou outras agressões ao coração causadas por estilo de vida e condições de doença. a invenção se refere também a um método de extração e purificação com alto rendimento de garcinol 95-99% puro a partir da espécie garcinia e a um método para complexar quimicamente garcinol com ciclodextrinas para melhorar sua estabilidade e biodisponibilidade.
BR112013014387A 2010-12-09 2011-01-25 complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição BR112013014387B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3765CH2010 2010-12-09
PCT/IB2011/050316 WO2012076988A1 (en) 2010-12-09 2011-01-25 A complex of garcinol, cyclodextrin and method thereof

Publications (2)

Publication Number Publication Date
BR112013014387A2 BR112013014387A2 (pt) 2016-09-27
BR112013014387B1 true BR112013014387B1 (pt) 2020-04-28

Family

ID=46199602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014387A BR112013014387B1 (pt) 2010-12-09 2011-01-25 complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição

Country Status (10)

Country Link
US (2) US20120148504A1 (pt)
EP (1) EP2649035B1 (pt)
JP (1) JP5804432B2 (pt)
KR (1) KR101654832B1 (pt)
CN (1) CN103459362B (pt)
AU (1) AU2011340203B2 (pt)
BR (1) BR112013014387B1 (pt)
CA (1) CA2820984C (pt)
RU (1) RU2566065C2 (pt)
WO (1) WO2012076988A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015049553A1 (en) * 2013-10-03 2015-04-09 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy
EP3614846A4 (en) * 2017-06-22 2021-01-13 Sami Labs Limited GARCINOL COMPOSITIONS FOR THE THERAPEUTIC MANAGEMENT OF STRESS IN THE ENDOPLASMATIC RETICULUM
CN108191662B (zh) * 2018-01-17 2020-10-23 石家庄学院 一种山竹醇衍生物及应用
US11052125B2 (en) * 2018-04-30 2021-07-06 Sami Labs Limited Compositions for weight loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972357A (en) * 1996-12-19 1999-10-26 Kikkoman Corporation Healthy foods and cosmetics
US6464988B1 (en) * 2001-05-09 2002-10-15 Usv Limited Glipizide-cyclodextrin inclusion complexes and their pharmaceutical composition
JP2003231607A (ja) * 2002-02-05 2003-08-19 Hosoda Shc:Kk マンゴスチン抽出物及びその含有抗菌消臭剤
JP2004305116A (ja) * 2003-04-08 2004-11-04 Nippon Shokuhin Kako Co Ltd 飲食物およびその製造方法
WO2005004923A1 (ja) * 2003-07-10 2005-01-20 Kyowa Hakko Kogyo Co., Ltd. 錠剤およびその製造方法
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
IN2003CH00929A (pt) * 2003-11-13 2008-10-06
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
WO2008079868A1 (en) * 2006-12-22 2008-07-03 Drugtech Corporation Clonidine composition and method of use
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
CA2820984A1 (en) 2012-06-14
RU2013131247A (ru) 2015-03-20
US20120148504A1 (en) 2012-06-14
AU2011340203A1 (en) 2013-06-27
WO2012076988A1 (en) 2012-06-14
BR112013014387A2 (pt) 2016-09-27
CN103459362B (zh) 2015-11-25
KR101654832B1 (ko) 2016-09-06
CN103459362A (zh) 2013-12-18
US9956301B2 (en) 2018-05-01
JP2014503514A (ja) 2014-02-13
EP2649035A4 (en) 2016-08-31
JP5804432B2 (ja) 2015-11-04
AU2011340203B2 (en) 2015-11-26
RU2566065C2 (ru) 2015-10-20
EP2649035A1 (en) 2013-10-16
KR20130122767A (ko) 2013-11-08
CA2820984C (en) 2016-10-11
US20150196669A1 (en) 2015-07-16
EP2649035B1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
EA201291168A1 (ru) Фармацевтические композиции и способы их получения
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
PH12015501678A1 (en) Inhibitors of influenza viruses replication
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2012083122A8 (en) Inhibitors of influenza viruses replication
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112014019667A2 (pt) formulação de anticorpo abeta
BR112015017069A2 (pt) processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo
BR112013014387B1 (pt) complexo de garcinol e ciclodextrina, seu proceso de preparação, processo para extrair garcinol, e composição
BR112015021856A2 (pt) processos e intermediários para a preparação de um medicamento
EA201190297A1 (ru) Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их получения и применения
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112012015977A2 (pt) composto derivado de poli (ácido lático), método para preparar o composto derivado de poli (ácido lático), complexo do composto de derivado de poli (ácido lático), composição de liberação prolongada de droga, e, método para preparar a composição de liberação prolongada de droga
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
EA201491994A1 (ru) Способы комплексообразования с циклодекстринами для введения пептидных протеасомных ингибиторов в фармацевтические составы
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
MA38646A1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
RU2014133697A (ru) Композиция глазных капель

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2011, OBSERVADAS AS CONDICOES LEGAIS.